Overview

Metformin and Congenital Nephrogenic Diabetes Insipidus

Status:
Terminated
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether metformin can increase urine concentration (osmolality) and decrease the amount of urine in patients with congenital nephrogenic diabetes insipidus (NDI).
Phase:
Phase 1
Details
Lead Sponsor:
Emory University
Treatments:
Arginine Vasopressin
Metformin